Janssen Submits Application to the European Medicines Agency for RYBREVANT^®▼ (Amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations

“People living with advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations generally face a poor survival probability, and new treatment options are urgently needed from the very first line of therapy,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH.